Equities research analysts expect Paratek Pharmaceuticals Inc (NASDAQ:PRTK) to post sales of $11.89 million for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Paratek Pharmaceuticals’ earnings, with estimates ranging from $11.50 million to $12.47 million. Paratek Pharmaceuticals reported sales of $3.93 million during the same quarter last year, which indicates a positive year over year growth rate of 202.5%. The firm is scheduled to issue its next quarterly earnings report on Tuesday, November 10th.

On average, analysts expect that Paratek Pharmaceuticals will report full year sales of $80.94 million for the current year, with estimates ranging from $78.00 million to $83.00 million. For the next financial year, analysts expect that the firm will report sales of $145.16 million, with estimates ranging from $120.44 million to $168.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Paratek Pharmaceuticals.

Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its quarterly earnings results on Monday, August 10th. The specialty pharmaceutical company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.39). The business had revenue of $9.33 million during the quarter, compared to the consensus estimate of $34.34 million.

A number of analysts have recently commented on PRTK shares. HC Wainwright upped their price objective on Paratek Pharmaceuticals from $18.00 to $19.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. ValuEngine upgraded Paratek Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 11th. Zacks Investment Research downgraded Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 12th. SVB Leerink dropped their price objective on Paratek Pharmaceuticals from $15.00 to $14.00 and set an “outperform” rating for the company in a report on Tuesday, August 11th. Finally, BidaskClub upgraded Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $15.71.

PRTK stock opened at $5.83 on Thursday. The company has a market cap of $264.61 million, a price-to-earnings ratio of -1.94 and a beta of 1.53. The business has a fifty day simple moving average of $4.66 and a 200-day simple moving average of $4.44. Paratek Pharmaceuticals has a 52 week low of $2.50 and a 52 week high of $6.41.

A number of hedge funds and other institutional investors have recently made changes to their positions in PRTK. BlackRock Inc. increased its holdings in Paratek Pharmaceuticals by 3.7% in the 1st quarter. BlackRock Inc. now owns 2,408,849 shares of the specialty pharmaceutical company’s stock valued at $7,588,000 after purchasing an additional 84,937 shares in the last quarter. Citigroup Inc. increased its holdings in Paratek Pharmaceuticals by 32.2% in the 1st quarter. Citigroup Inc. now owns 14,227 shares of the specialty pharmaceutical company’s stock valued at $45,000 after purchasing an additional 3,469 shares in the last quarter. BNP Paribas Arbitrage SA grew its stake in shares of Paratek Pharmaceuticals by 121.2% during the first quarter. BNP Paribas Arbitrage SA now owns 10,164 shares of the specialty pharmaceutical company’s stock valued at $32,000 after acquiring an additional 5,570 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Paratek Pharmaceuticals during the first quarter valued at about $61,000. Finally, Nuveen Asset Management LLC grew its stake in shares of Paratek Pharmaceuticals by 82.2% during the first quarter. Nuveen Asset Management LLC now owns 193,457 shares of the specialty pharmaceutical company’s stock valued at $610,000 after acquiring an additional 87,258 shares in the last quarter. Hedge funds and other institutional investors own 46.77% of the company’s stock.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris.

Featured Story: What economic reports are most valuable to investors?

Get a free copy of the Zacks research report on Paratek Pharmaceuticals (PRTK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.